Hereditary Cancer Screening and Outcomes at an Urban Safety-Net Hospital

Medicine, Medical Laboratory Science, Oncology, Life Sciences, Genetics,
Hereditary Cancer Syndromes   Genetic Testing   Cancer Risk   Urban Hospital   Ethnic Minorities   Disparities   Cancer Care  

Screening and Outcomes of Hereditary Cancer Syndromes: A Study at an Urban Safety Net Hospital Study Background Patients with Hereditary Cancer Syndromes (HCS) have a higher lifetime risk of developing cancer. Historically, underserved populations have lower rates of genetic evaluation. Hence, researchers aim to understand the demographic factors i...

Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets

Medicine, Medical Laboratory Science, Oncology, Life Sciences, Biochemistry, Immunology,
Undifferentiated Sarcomatoid Carcinoma   Pancreatic Cancer   Genomic Profiling   Therapeutic Targets   Immune Checkpoint Inhibitors  

Genomic Characteristics of a Rare Pancreatic Cancer Undifferentiated Sarcomatoid Carcinoma Subtype Academic Background Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by early invasion and metastasis. Undifferentiated Sarcomatoid Carcinoma (USC) is a particularly aggressive but rare subtype of PDAC, accounting...

Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2–Positive Disease

Medicine, Neurology, Oncology, Life Sciences, Cell Biology, Biochemistry, Genetics,
breast cancer   brain metastasis   structural rearrangement   cyclin-dependent kinase 12   HER2   genomics   targeted therapy  

Research Report on CDK12 Structural Rearrangements in Brain Metastases of Breast Cancer Background and Purpose Breast Cancer (BC) is the second most common solid tumor involving the Central Nervous System (CNS). Brain Metastases from Breast Cancer (BCBMs) are becoming increasingly common among patients with metastatic breast cancer. Patients with a...

High-Dimensional Mapping of Human CEACAM1 Expression on Immune Cells and Association with Melanoma Drug Resistance

Medicine, Oncology, Life Sciences, Cell Biology, Bioengineering, Immunology,
CEACAM1   immune cells   melanoma   drug resistance   tumor microenvironment   immune checkpoint  

The Expression of High-Dimensional Mapping of Human CEACAM1 on Immune Cells and Its Association with Melanoma Drug Resistance Research Background Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) is an inhibitory cell surface protein that acts through homophilic and heterophilic ligand binding. The expression of this protein...

Age-dependent Loss of Hapln1 Erodes Vascular Integrity via Indirect Upregulation of Endothelial ICAM1 in Melanoma

Medicine, Medical Laboratory Science, Geriatrics, Oncology, Cardiovascular System, Life Sciences, Cell Biology, Biochemistry, Immunology,
Hapln1   Melanoma   Vascular Integrity   ICAM1   Aging   Extracellular Matrix  

Age-dependent loss of HAPLN1 erodes vascular integrity via indirect upregulation of endothelial ICAM1 in melanoma In a research article titled “Age-dependent loss of HAPLN1 erodes vascular integrity via indirect upregulation of endothelial ICAM1 in melanoma” published in Nature Aging in March 2024, significant findings have been revealed. The study...

Epithelial−Mesenchymal Transition Induced by Tumor Cell-Intrinsic PD-L1 Signaling Predicts a Poor Response to Immune Checkpoint Inhibitors in PD-L1-High Lung Cancer

Medicine, Rheumatology and Immunology, Respiratory System, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
PD-L1   Epithelial-Mesenchymal Transition   Non-Small-Cell Lung Cancer   Immune Checkpoint Inhibitors   Biomarkers   Tumor Progression  

Tumor Cell-Intrinsic PD-L1 Signaling Induces Epithelial-Mesenchymal Transition (EMT) Predicting Poor Response to Immune Checkpoint Inhibitors in PD-L1 High-Expressing Lung Cancer Research Background and Motivation In cancer immunotherapy, Programmed Death Ligand-1 (PD-L1) inhibits immune responses by binding to Programmed Death-1 (PD-1) receptors o...